Brief: Theravance Biopharma Reports Phase 3 Cypress Study Did Not Meet Primary Endpoint Board Accelerates Strategic Review And Announces Cost Reduction Actions

Theravance Biopharma

03/03/2026 13:33

March 3 (Reuters) - Theravance Biopharma Inc TBPH.O:

THERAVANCE BIOPHARMA REPORTS PHASE 3 CYPRESS STUDY DID NOT MEET PRIMARY ENDPOINT; BOARD ACCELERATES STRATEGIC REVIEW AND ANNOUNCES COST REDUCTION ACTIONS

THERAVANCE BIOPHARMA REPORTS PHASE 3 CYPRESS STUDY DID NOT MEET PRIMARY ENDPOINT; BOARD ACCELERATES STRATEGIC REVIEW AND ANNOUNCES COST REDUCTION ACTIONS

THERAVANCE BIOPHARMA INC: PHASE 3 CYPRESS STUDY DID NOT MEET PRIMARY ENDPOINT

THERAVANCE BIOPHARMA INC: STRATEGIC REVIEW COMMITTEE ACCELERATING ONGOING EFFORTS TO EVALUATE ALTERNATIVES TO MAXIMIZE SHAREHOLDER VALUE

THERAVANCE BIOPHARMA INC: ORGANIZATIONAL RESTRUCTURING TO REDUCE COST BASE BY APPROXIMATELY 60%

THERAVANCE BIOPHARMA INC: ORGANIZATIONAL RESTRUCTURING TO REDUCE COST BASE BY APPROXIMATELY 60% (OR APPROXIMATELY $70 MILLION)

THERAVANCE BIOPHARMA INC:  RESTRUCTURING EXPECTED TO RESULT IN COMPANY GENERATING APPROXIMATELY $60 - $70 MILLION OF ANNUALIZED CASH FLOW

THERAVANCE BIOPHARMA INC: RESTRUCTURING EXPECTED TO RESULT IN COMPANY GENERATING APPROXIMATELY $60 - $70 MILLION OF ANNUALIZED CASH FLOW

THERAVANCE BIOPHARMA INC: RESTRUCTURING IS EXPECTED TO IMPACT APPROXIMATELY 50% OF OVERALL WORKFORCE

THERAVANCE BIOPHARMA INC: REDUCTION INCLUDES COMPLETE WIND-DOWN OF RESEARCH AND DEVELOPMENT ORGANIZATION AND A DECREASE OF APPROXIMATELY 50% IN G&A EMPLOYEES

THERAVANCE BIOPHARMA INC: EXPECTS TO INCUR APPROXIMATELY $5 TO $7 MILLION IN ONE-TIME CASH SEVERANCE COSTS

Source text: ID:nPn5Znz84a

Further company coverage: TBPH.O

 ((Reuters.Briefs@thomsonreuters.com;))